Pancreatic ductal adenocarcinoma is brutal partly because it gets very good at ignoring chemotherapy. One reason is something called epithelial-to-mesenchymal transition, or EMT. In normal biology, EMT helps cells become more mobile during development and wound repair. In cancer, it is more like a jersey swap in the fourth quarter. Tumor cells stop acting like orderly stay-at-home cells and start behaving like slippery road warriors that move, adapt, and shrug off treatment.
That is where netrin-1 enters the game. Netrin-1 is better known as a developmental guidance signal, basically one of the body’s old wiring instructions. Cancer, being an absolute thief of other people’s homework, can reuse that signal to help tumors grow, spread, and resist therapy. Recent reviews have framed EMT as a central engine of tumor plasticity and treatment escape, not some side quest scientists added for drama (Jimenez-Castaño and Nieto, 2026).
NP137 Enters The Match
The new study tested an antibody called NP137, which blocks netrin-1, in combination with modified FOLFIRINOX for people with locally advanced pancreatic cancer (Roth et al., 2026). FOLFIRINOX is already one of the main heavy hitters here. It is effective, but it is also the chemo equivalent of sending four linebackers through your front door.
This was a phase 1b trial, so the first job was safety, not a victory parade. The team enrolled 43 patients. The combo was reported as well tolerated, with a median progression-free survival of 10.85 months and median overall survival of 16.43 months. Among 41 evaluable patients, 12 had partial responses, 27 had stable disease, and the disease control rate reached 95%. Also worth a raised eyebrow: 23% of patients went on to surgery after treatment.
For pancreatic cancer, that last stat matters. A lot. Surgery is still the only route with real curative intent for many patients, but locally advanced disease often keeps that door nailed shut. If a drug combo helps more tumors become operable, that is not a small tactical gain. That is your underdog team suddenly making the playoffs.
Why Blocking Netrin-1 Might Matter
The interesting part is not just that patients did somewhat better than you might expect. It is why. The researchers found that the main pathway pushed down by NP137 plus chemotherapy was EMT. Translation: the treatment may be helping chemo by stopping tumor cells from slipping into one of their most evasive disguises.
That idea did not come out of nowhere. In 2023, another Nature study showed NP137 reduced EMT features in endometrial cancer and appeared to make tumors more sensitive to chemotherapy (Cassier et al., 2023). Pancreatic cancer already had preclinical evidence pointing the same way. Netrin-1 has been tied to pancreatic tumor growth, innervation, and metastasis (Haidar et al., 2025); (Dudgeon et al., 2023).
In other words, NP137 is not being drafted as a miracle solo act. It looks more like a defense specialist brought in to stop the tumor’s favorite play: becoming more plastic, more invasive, and more chemo-resistant.
The Biomarker Plot Twist
There was also a nice bit of scouting report drama. Patients whose tumors had high expression of the netrin-1 receptor neogenin did especially well, with median progression-free survival of 15.65 months versus 10.22 months in the neogenin-low group (Roth et al., 2026).
That matters because pancreatic cancer treatment still suffers from a recurring problem: too much guessing, not enough matchmaking. If neogenin helps identify who actually benefits from netrin-1 blockade, this moves from “interesting molecule” territory toward “useful game plan.”
Slow Down, ESPN
Before we start engraving NP137’s Hall of Fame plaque, a few reality checks. This was a small, single-arm early-phase study. There was no randomized control arm, so we cannot say with confidence how much of the outcome came from NP137 versus the chemo backbone and patient selection. Pancreatic cancer has embarrassed many promising contenders before. The sport is mean like that.
Still, the concept is strong. Pancreatic tumors are hard to kill not just because they grow fast, but because they adapt fast. If you can block one of the switches that helps them change shape and dodge damage, you may give standard chemotherapy a cleaner shot at the target.
That is the real appeal here. Not wizardry. Not hype. Just a smart attempt to stop the tumor from rewriting the playbook mid-game.
References
- Roth G, Artru P, Bouche O, et al. Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer. Nature. 2026. DOI: https://doi.org/10.1038/s41586-026-10436-4
- Jimenez-Castaño R, Nieto MA. Epithelial-to-mesenchymal transition as a central driver of tumor cell plasticity. Nature Cancer. 2026. DOI: https://doi.org/10.1038/s43018-026-01154-x
- Cassier PA, et al. Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer. Nature. 2023;620:409-416. DOI: https://doi.org/10.1038/s41586-023-06367-z
- Haidar H, Bellon A, Sleiman K, et al. Neural function of Netrin-1 in precancerous lesions of the pancreas. Nature Communications. 2025;16:7094. DOI: https://doi.org/10.1038/s41467-025-62299-4
- Dudgeon C, et al. Netrin-1 feedforward mechanism promotes pancreatic cancer liver metastasis via hepatic stellate cell activation, retinoid, and ELF3 signaling. Cell Reports. 2023;42:113369. DOI: https://doi.org/10.1016/j.celrep.2023.113369
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.